With a strong launch underway for a bladder cancer gene therapy, Ferring Pharmaceuticals is finding the kind of commercial ...

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Countdown Begins to November 18, 2025 PDUFA for Plozasiran Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is developing plozasiran for the ...

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story ACA premiums set to spike People who buy ...

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...